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My attitude toward studying mutation in
human fibroblasts at this time is related to
that expressed by Dylan Thomas in a note
to his "Collected Poems" (1): "I read some-
where of a shepherd who, when asked why
he made, from within fairy rings, ritual
observances to the moon to protect his flocks,
replied: 'I'd be a damn fool if I didn't!' These
poems, with all their crudities, doubts, and
confusions, are written for the love of man
and in praise of God, and I'd be a damn
fool if they weren't."
The experimental study of mutation in
diploid human cells is in its infancy and
is still prey to crudities, doubts and con-
fusion in comparison to some submammalian
mutation detection systems that are tech-
nically neat and genetically characterized.
It is generally assumed that, ultimately, we
will want to use human cells for mutagenesis
detection, but that this will not be pos-
sible for some time to come because of their
technical limitations. I will submit two pro-
positions for your consideration: (1) tech-
nical limitations in using diploid human cells
are far from decisive and several opport-
unities for detailed mutation studies are now
available; (2) presented with opportunities
for making these studies, "I'd be a damn
fool if I didn't!"
My plan in this presentation is to sum-
marize with little documentation some on-
going studies of hereditary variation in cult-
ured human fibroblasts. Many of the details
are available in papers that are published
(2, 3) or submitted for publication (4). I
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will try to use only the details needed to
define the present status of the studies and
the main questions that must be answered
if they are to become useful for mutagenesis
detection in human cells.
Human Cells for Mutation Studies
Cultures of skin fibroblasts that are us-
able for mutation studies can be obtained
from virtually any human. Comparisons of
cultures from different humans will allow
us to derive information about cell genetics
that is representative of humanity. A corol-
lary advantage of this approach is the op-
portunity to relate the genetic behavior of
cells in vitro to the inheritance of genetic
factors in families: in favorable cases, pedi-
gree analysis will provide part of the evi-
dence that cells with altered phenotypes are
genetic variants. These advantages might
appear to be overridden by two often-cited
technical limitations of diploid fibroblasts:
low cloning efficiency and limited life span.
Cloning efficiencies from laboratories in
different nations often range from 0.2 to 0.8.
Subcloning efficiencies sometimes fall in this
range, too, and are large enough for practi-
cal work in many cases. Low cloning effi-
ciencies are often limitations of investiga-
tors or laboratory conditions, not fibro-
blasts.
Life span is still an ineluctable limita-
tion, which just hasn't prevented us and
others (5,6) from making progress in the
study of mutation. The number of doublings
allotted to fibroblasts in vitro is usually es-
timated at 50-60. Only about 20 doublings
are used when a single mutant cell generates
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analysis, quantitative growth studies and
sensitive enzyme determinations. This often
leaves many doublings that can be used to
generate large cell populations for partial
enzyme purification or other chemical deter-
minations and for genetic experimentation,
such as subcloning in the absence of selec-
tive agents, selection for revertants and
somatic cell hybridization. These comments
should not be interpreted as special pleading
for the adoption of human fibroblasts as the
subject for mutagenesis testing. My basic
attitude is that fibroblasts are the closest
convenient approximations to normal cul-
tured human cells that are currently avail-
able. They should be used for what they can
provide in the way of raw materials for de-
veloping mutagenesis methods and as one
standard of realism to be used in evaluating
the results that are obtained with the meth-
ods. I will make a few comments about fibro-
blasts in relation to other mammalian cells
after I have described some genetic results.
Resistance to 8-Azaguanine
Hereditary cell variants that are resistant
to 8-azaguanine (AG) can be detected in fi-
broblast cultures derived from apparently
any human, male or female. The average in-
cidence of AG-resistant (AGr) clones is
about 5 x 10-6 (2). A simple principle is
applied in detecting the mutants. AG, as
such, is innocuous to cells at 10-6-10-4M
concentration but is converted to a toxic
monoribonucleotide by the enzyme HG-PRT
in normal cells (Fig. 1). HG-PRT is a dis-
pensable enzyme under ordinary conditions,
so that HG-PRT-deficient mutants can grow
out as AGr colonies in the presence of AG.
The cells in the colonies can be isolated and
grown into large cell populations for further
characterization. This is one of the specially
favorable aspects of studying AGr variants:
they result from loss or reduction of a func-
tion that is non-essential under the condi-
tions of selection, so that mutants with a
wide range of phenotypic expressions can
be recovered. However, an absolute depen-
FIGURE 1. Purine nucleotide synthesis and inter-
conversions (simplified). Symbols are explained
in text where necessary.
dence on HG-PRT can be created by block-
ing the de novo pathway of purine nucleo-
tide biosynthesis with azaserine ([AS]). In
this circumstance, cells grow only if they
can convert an exogenous purine to the cor-
responding nucleotide. In normal fibroblasts
the two purines that work best are hypoxan-
thine (H) and adenine (A). Figure 1 shows
that the enzyme A-PRT can convert A to its
nucleotide, which can then be converted to
IMP and, then, GMP. Similarly, cells that
have HG-PRT can grow in a medium con-
taining hypoxanthine and azaserine (i.e.,
H[AS] medium). AGr mutants that lack
HG-PRT are expected to be arrested in
H[AS] medium.
In principle, the mutational study of AG
resistance has genetic advantages. The only
mutations known to markedly alter the
amount of activity and the properties of
HG-PRT in man are in X-chromosomal
genes. This means that single mutations in
these genes should be phenotypically mani-
fested as AG-resistance in male cells, having
one X, and in female cells, too: although
they have two X chromosomes the genes on
only one of them are phenotypically ex-
pressed. With male cells, at least, one should
almost automatically detect only gene muta-
tions and small deletions, since large dele-
tions and total loss of the X are likely to
cause cell death. To begin with, then, AG-'
resistance would appear to provide a chemi-
cally and genetically tidy system for quan-
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Here are some observations.
Properties of AGr Mutant Fibroblasts
Two broadly defined categories of spon-
taneous mutants have been observed. Type I
mutants have very low HG-PRT activity
and are unable to grow in H[AS]. These mu-
tants resemble cells cultured from boys hav-
ing X-chromosomal mutant alleles that
cause the Lesch-Nyhan syndrome and have
the properties we expected to find in AGr
mutants. However, only three Type I mu-
tants have been found among 20 indepen-
dent, spontaneous mutants tested. About
85%o of the mutants are Type II. The range
of apparent HG-PRT activities in these mu-
tants extends from Type I amounts to those
found in normal cells. Almost all of them
have distinct reductions in apparent HG-
PRT activity but all of them can grow in
H[AS]. Type II mutants resemble cells from
some humans who have X-chromosomal mu-
tant alleles that change the properties and
reduce the function of HG-PRT but do not
cause the Lesch-Nyhan syndrome (2).
Is AG Resistance a Stable Hereditary
Change?
Several independent mutants have been
subcloned in the absence of AG and shown
to retain their characteristic AG resistance,
HG-PRT activity, and ability or inability
to grow in H[AS], depending on whether
they were Type I or Type II. We think that,
at least in most cases, AG resistance asso-
ciated with reduced HG-PRT activity is not
an adaptation induced in the presence of
AG and readily reversible in its absence.
This notion is supported by the results of
several fluctuation tests, which provided
evidence that most AG-resistant colonies re-
sulted from changes in cell heredity that
occurred before the cells were subjected to
selection with AG. The averaged upper and
lower estimates of the rate of spontaneous
origin of AG-resistance are 0.34 to 1.34 x
10-6 per cell generation (2).
----ehanges, i.e., from Changes in Genes or
Ghromosomes?
There are various ways of trying to an-
swer this question; head-on enzymology is
one of them. We have shown that the resid-
ual HG-PRT activity of a Type I mutant
had abnormal thermolability and a dis-
tinctly increased affinity for one of its sub-
strates, PRPP (2). One Type II mutant had
a distinctly abnormal pH optimum (unpub-
lished data). This sort of characterization
of mutants will finally permit estimation of
the fraction of independent mutations that
cause abnormalities in HG-PRT other than
simple reductions in activity. Electrophore-
tic alterations have not been observed yet
but methods with greater resolving power
will be tried. Finally, Dr. Karsten Held has
prepared antibodies against partially puri-
fied HG-PRT so that, using a sensitive
serum-blocking test, we can determine if
enzyme-deficient mutants have an amount
of antigenically reactive protein in excess of
that corresponding to the apparent HG-PRT
activity. Such excesses would be evidence
that the mutations had altered the proper-
ties of the enzyme protein and not merely
reduced the amount of enzyme produced by
the cells.
It would be surprising if a variety of
regulatory mutations affecting HG-PRT did
not occur. In a general sense, some of them
could correspond to cis-dominant operator
and promoter mutations or trans-dominant
regulator mutations in bacteria. Mutations
affecting post-transcriptional processes in-
fluencing the amount of HG-PRT activity
might also occur e.g. messenger RNA sta-
bility, stabilization of the enzyme protein or
processing of HG-PRT zymogen, if such oc-
curs. Excepting the analogs of operator and
promoter mutations associated with the
structural gene on the X, mutations reduc-
ing HG-PRT activity could occur on any
chromosome. Therefore, we have set out to
map AG-resistance mutations to a chromo-
some by means of somatic cell hybridiza-
tion. The principle is now familiar. Most
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in H[AS]. By use of Sendai virus, Type II
mutants are fused with a nonreverting mu-
tant of mouse cell clone ID that is AGr,
HG-PRT-deficient and unable to grow in
H[AS]. In this medium, mouse parental
cells are quickly and totally eliminated. Hy-
brid cells are readily identified by their
morphology and ability to grow as discrete
colonies upon a background of Type II mu-
tant, human cells. They are then isolated
and propagated as pure cultures in H[AS]
medium. Human chromosomes are grad-
ually eliminated from the hybrid cells until
only those remain that bear the genes neces-
sary for growth in the selective medium.
Therefore, we expect to find the human X-
chromosome because it bears structural
genes for HG-PRT. If AG-resistance in Type
II mutants results directly from a change in
an X-chromosomal gene, the H[AS]-
selected hybrids should still be AG-resistant
and have HG-PRT activity that corre-
sponds qualitatively and quantitatively to
that present in the human cell parent. AG-
resistance might be phenotypically and ge-
netically more complicated in some cases.
For instance, full resistance to AG in Type
II mutants might require two conditions:
(1) a mutation in an X-chromosomal gene
that reduced HG-PRT activity but not
enough to, by itself, reduce the production
of AG-nucleotide to sub-toxic amounts; (2)
the overproduction of purines by the de novo
pathway, which occurs in cells from HG-
PRT-deficient humans. The excess normal
nucleotides might minimize the effects of
AG-nucleotide. If genes necessary for the
overproduction are located on autosomes two
relevant types of clones may segregate out
of H[AS]-selected hybrids: clones retain-
ing only the human X, which are either sen-
sitive or slightly resistant to AG but whose
HG-PRT may, nevertheless, be demon-
strably abnormal; AG-resistant clones re-
taining the human X and at least one other,
specific, human chromosome.
If AG resistance resulted from the trans-
dominant effect of an autosomal mutation
on a normal X-chromosomal HG-PRT locus
then, again, two types of clones might segre-
gate from H[AS]-selected hybrids: AG-
sensitive clones retaining only the human
X and producing qualitatively and quanti-
tatively normal human HG-PRT; AG-
resistant clones that retain the human X
and at least one other, specific, human
chromosome. HG-PRT activity would be re-
duced but qualitatively normal.
Other genetic bases for AG resistance are
conceivable but will not be discussed. My
object is simply to emphasize that it will be
possible to attempt a genetic analysis of the
commonest type of AGr mutants of human
fibroblasts. Three crosses with independent
Type II mutants are in progress. One was
performed with cells from the human pro-
totype of Type II mutants, which I men-
tioned above. In this case, we know that the
HG-PRT is qualitatively altered as the re-
sult of a mutation in an X-chromosomal
gene (2). Therefore, the properties of hy-
brids obtained with this mutant will provide
a standard for evaluating the results ob-
tained with in vitro mutants. Furthermore,
the AG resistance and HG-PRT activity of
these hybrids can be compared with those of
H[AS]-selected hybrids produced from the
same strain of mouse cells and normal, AG-
sensitive human cells. Subclones of the first
hybrid to be analyzed so far are still AG-
resistant. The other two crosses utilized
Type TI mutants that originated in vitro.
HrAS]-selected hybrids have been obtained.
These studies are obviously incomplete but
should finally tell us whether or not the
commonest type of AGr mutants result
from changes that can be assigned to speci-
fic human chromosomes.
If an adequately firm genetic foundation
for AG-resistant mutations in human cells
can be laid down, additional information
will be needed to make them useful for
mutagenesis testing. First, we should deter-
mine that the mutation-detection method is
responsive to known mutagens. Some infor-
mation is available but more is needed.
There is published evidence that x-rays in-
crease the rate of mutation to AG resistance
(3) and evidence, to be published, that
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(7). Second, more reliable and representa-
tive estimates of the rate of spontaneous
mutation are needed, since this is the most
useful standard for quantitatively evaluat-
ing mutagenic effects, especially small ones.
These estimates are best derived from fluc-
tuation tests, some repeated, with cultures
from a number of humans of different sexes
and races.
Resistance to 2,6-Diaminopurine
The preceding discussion makes possible
a concise description of a second selection
system, which Dr. Harriet Rappaport and I
have recently been studying with human
cells (4). 2,6-Diaminopurine (DAP) is an
adenine analog that becomes toxic to cells
when converted to a ribonucleotide by the
enzyme A-PRT (Fig. 1). A-PRT is dispens-
able under ordinary conditions of growth,
and enzyme-deficient mutants should be se-
lected for when DAP is present. Further-
more, if the de novo pathway is blocked
with [AS], normal cells should be able to
grow in a medium containing adenine as
the sole exogenous purine (i.e., A[AS] med-
ium), but A-PRT-deficient cells should be
unable to do so.
DAP-resistant (DAPr) fibroblast clones
have been recovered from 13 people belong-
ing to 11 unrelated families. Two general
categories of mutants occur, corresponding
to the two categories of AGr mutants. Type
I mutants have very low A-PRT activity
and are unable to grow in A[AS]. One Type
I mutant has been found so far among at
least four independent mutants that we have
studied.
Type II mutants have had apparent
A-PRT activities ranging between about
0.2 of normal and normal but all can grow
well in A[AS]. One mutant with about 0.02
of normal activity had only a slight ability
to grow in A[AS]. Individual subclones of
Type II mutants that initiate growth in
DAP can continue growth when the med-
ium is replaced with A[AS]. Finally, since
all of the mutants increased manyfold in
the absence of DAP before they were char-
acterized we believe that DAP resistance is
a stable hereditary alteration of normal
cells.
From the outset we expected the genetics
of DAP resistance to be more complicated
than that of AG resistance and that it would
be difficult to obtain mutants. There was
evidence that A-PRT was determined by
autosomal genes. Dr. Brenda Kahan and I
have since determined that hybrids of nor-
mal human fibroblasts and A-PRT-deficient
mouse cells isolated by selection for ability
to utilize adenine characteristically retain
human autosome No. 16 (to be published).
We expected DAP resistance to be recessive
in heterozygous cells and, therefore, our at-
tempts to obtain DAPr mutants began with a
search for heterozygous people: only in
heterozygous cell populations would homo-
zygous mutants resulting from single genetic
changes be frequent enough to permit prac-
tical experimentation. The rationale used in
identifying heterozygous cultures was sim-
ple and successful. It is described here as
an idea because it should be applicable in
developing new selection methods for human
cells.
There was only one report of hereditary,
partial A-PRT deficiency, which was non-
pathological. If homozygosity for deficiency
alleles was lethal before birth, a heterozy-
gote incidence of 1/200 to 1/25 was fairly
likely, to judge from the frequency of many
deleterious, autosomal recessive genes. Al-
ternatively, A-PRT variation could be in-
nocuous and might have escaped notice be-
cause the commonest variant alleles neither
altered the electrophoretic behavior nor the
apparent activity of the enzyme. Nonpatho-
logical allelic variations of some other en-
zymes occur with frequencies of 0.1-0.5. In
either case, then, there was a reasonable
chance of identifying a heterozygote if we
examined as few as 200 people using the
right kind of detection method.
A discontinuous variable was used to dis-
tinguish between normal and heterozygous
cell cultures. The rate of spontaneous muta-
tion to AG-resistance is, roughly, 10-6 per
cell generation. Assuming this is a typical
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DAPr mutants should- be undetectable in
samples of 106 homozygous normal cells but
should often be detected in similar samples
of 106 heterozygous cultures. We sim-
ply cultured foreskin fibroblasts from nor-
mal newborns and subjected samples of
about 106 cells from each boy to selection
with DAP after a mutagenic treatment
with MNNG. The treatment was known to
increase the rate of mutation to AG-
resistance 10 to 100 times and raised the
probability of detecting mutants in hetero-
zygous cultures without permitting their de-
tection in homozygous cultures. These
small-scale mutagenesis experiments
worked. DAPr mutants having the pheno-
types described above were detected in
eleven unrelated, foreskin-derived cultures
among 83 that were grown.
Our estimate of the incidence of apparent
heterozygosity is in the range 0.1 to 0.5.
Such estimates are useful in planning fur-
ther studies but do not prove the hypothesis
on which they are founded. They will not
mean much with regard to mutagenesis
testing until the actual genetic basis for
DAP resistance is worked out.
Genetic Analysis of DAP Resistance
According to the hypothesis that DAPr
mutants originate in cultures of cells that
are heterozygous for A-PRT deficiency al-
leles, boys whose cultures yield mutants
should have one parent, sometimes two par-
ents, who should be heterozygous and whose
cultures should yield mutants. This will less
frequently be true for boys whose cultures
fail to yield DAPr mutants and quantities
can be assigned to these expectations as our
estimates of the allelle frequencies improve.
In two families studied so far, mutants
were recovered from just one parent of boys
yielding mutants. We hope these family
studies will show that the mutations we are
studying in vitro correspond to hereditary
factors in humans. Furthermore, if we can
define the inheritance of distinctive A-PRT
alleles in families the information will be of
great value in distinguishing between dif-
ferent possible genetic origins of DAPr mu-
tants, which are discussed below.
The approaches to biochemical and ge-
netic analysis of AG resistance that were de-
scribed above are also being used in charac-
terizing DAPr mutants. For instance, Type
II DAPr mutants, the commonest type, can
be fused with A-PRT-deficient mouse cells
and hybrids isolated in A[AS] selective
medium. The genetically simplest outcome
will be hybrids that are DAP-resistant and
retain human autosome No. 16. More com-
plicated outcomes, analogous to those men-
tioned above with reference to AG-
resistance, will not be discussed further
here. My main point is that a formal gene-
tic analysis of the commonest type of DAPr
mutant can be attempted.
These approaches will have to be comple-
mented by special studies of the mutant,
human cells, themselves. Selectable DAPr
variants could result from more than one
kind of genetic event involving autosome
No. 16 in cells that are already heterozy-
gous: (1) gene mutation; (2) terminal dele-
tion of the normal allele; (3) monosomy
for No. 16 resulting from simple loss or non-
disjunction of the homolog with the normal
allele; (4) somatic crossing over. There are
practical ways of distinguishing between all
of these possibilities, even between gene
mutation and somatic crossing over. I will
not discuss them here but want to empha-
size that these genetic processes have to be
evaluated in every mutation detection sys-
tem utilizing diploid cells, regardless of the
species from which they are derived.
The chance that phenotypic mutants will
originate from heterozygous cells through
processes other than gene mutation is
strongly influenced by two factors: distance
between the locus and the centromere and
deleterious effects of partial or complete
monosomy for the chromosome bearing the
locus. This suggests that cells with mutant
phenotypes will most often result from gene
mutations of some loci, from chromosome
mutations involving other loci and, perhaps,
from somatic crossing in some cases. A vig-
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systems for human cells and to analyze them prior doublings of the gonia in the case of
thoroughly may provide us with sensitive males. This number of doublings may per-
ways of screening for chromosome breaks tain--to some populations of somatic cells, too.
that are propagated (i.e., the- kind that' Therefore, an influence that doubled the mu-
cause trouble for people)- and, in addition,' -tation rate per cell generation wouldn't be
a possible cause of- somatic disease that re- detectable as a doubled incidence of mutants
ceives little serious consideration: somatic - until it had acted for about 50 doublings of
crossing over. a cell population. This means that direct test-
ing will promptly discover mutagenic effects
Some Perspectives in Mutagenesis only when they are very large and that less
Testing with Human Cells powerful influences may cause significant
damage before they are detected. I know of
Weonsof aoreintereted ionsintw relatd aplc- no way to eliminate or reduce the high back- tions of scoring mutations in human cells, ground of in vivo mutants that I have re-
ondtheonerned with mutagenesisdetfction. ferred to. It may be lower than I have esti-
andmthecothertwith mutagenoidenticatpossio mated and may be a smaller problem than I
Somatndicatorsofgerminal mutations areit ahave indicated. Little information is available ble indicators of germinal mutations that about the in vivo incidences of somatic cells
canors affectfuugenerdatnst cand hasrmd- with genetically defined mutations. The ac- cators of genetsc damages that can harm- cumulation of such information should be an
the individuals in which they occur. I think -explicit objective of the immediate future if
of the first application as "direct" testing direct testing is to become practical I hope
the incidences of mutants alreawdy~ ^present - -this will be achieved because experience indi-
among somatic or germinal cells are deter- cates that despite our efforts at prospective
mined immediately upon their-remnoveai:f. -m-diagnostic testing we are likely to discover
the bodies of a properly chosen sampll popu-h- some mutagens only after people have been
lation, before the cells have a chance to pro-- - ' exposed to them. Direct testing may provide
liferate outside the body. The main objec- a relatively sensitive method of discovering
tive of direct testing is the prompt detec- their effects before they are manifested as
tion of-mutagenic influences on cells in `VO. increased incidences of cancer, congenital
Such discovery must be followed up..by de- deformity, or disease.
tective work needed to identify the muta- The need for information about the in-
gen. cidences of mutant somatic cells in vivo in-
One problem associated with direct test- troduces the second difficulty with direct test-
ing is the cumulative incidence of mutants ing: deciding if a cell with a specific abnor-
that results from their proliferation after mal phenotype is a genetic variant or a phe-
they originate in a population of dividing nocopy. Mostly histochemical, serological, or
cells. This is the background above which other methods that kill individual cells in
mutagenic effects must be detected in vivo. the process of defining their phenotypes will
Its magnitude can be roughly. evaluated by be u-sed in direct testing. We will need back-
using information that is available now and ground genetic information, which will give
the assumption that mutation rates- are sim-' us confidence that a cell with a specific ab-
ilar in somatic and germinal ;cells- This[as- normal phenotype is probably a mutant and
sumption is not proven, but comparative in- - . not a phenocopy. One approach to solving formation has begun to accumulate. -The in * . l .................... l , this problem iS to choose mutant phenotypes -cidences of gametes having a mutation that
causes one specific human disease or another that almost certainly will not occur unless
is about lO5 to 10-4 for many human diseases. an individual has a specific genotype. The
This range represents the a-ccumulation-- jf- studies of diaminopurine resistance that I
mutants with regard to a single locus in a described exemplify this approach but one
133 December 1973would want to apply it using phenotypes
scorable in single cells for direct testing.
I think of the second application of scoring
mutations in human cells as "diagnostic"
testing. Its principal purpose is the identi-
fication of mutagens before they have acted
on people. Diagnostic testing could be exe-
cuted, in part, with cells proliferating in
vitro, where the problems of high back-
ground and genetic analysis are at least
partly overcome. Single abnormal cells can
be amplified into clonal populations, per-
mitting one to determine if an abnormal
phenotype is hereditary and to analyze it
chemically and in other ways. Genetic analy-
sis by means of karyotype study, complemen-
tation, and somatic cell hybridization is also
possible. Information obtained in this way
with cultured cells could be applied to the
development of methods for direct testing.
Here is an example of what I mean. While
Dr. Richard Albertini was studying in my
laboratory we tried to detect AG-resistant
circulating lymphocytes in normal individ-
uals. Our initial feasibility study involved
quantitating the incorporation of tritiated
thymidine into lymphocytes stimulated by
phytohemagglutinin in the presence of AG.
Comparisons of HG-PRT-deficient lympho-
cytes from boys who had the Lesch-Nyhan
syndrome with normal lymphocytes and art-
ificial mixtures of the two cell types showed
that the method was roughly quantitative
for the detection of AGr lymphocytes down
to about the one percent level. We detected
in normal lymphocyte populations an AG-
resistant incorporation that was about 1/
1000 that observed in the absence of AG (8).
The next step is to determine if this re-
sults mainly from slight incorporation into
all the cells or from very active incorpora-
tion into rare AGr cells. An obvious method
of tackling this question is to use autoradio-
graphic procedures that have been thoroughly
worked out with fibroblasts. An additional
method, derived from experience in bact-
eriophage genetics will also be tried. The
lymphocytes would be infected with vesicu-
lar stomatitis virus and the infected cells
would be introduced into a film of nutrient
agar atop a monolayer of AG-resistant mouse
cells, on which the virus could form plaques.
In the presence of AG, plaques would be
initiated only by AGr lymphocytes in which
the virus could multiply. The quantitative
sensitivity and accuracy of the method can
be ascertained with mixtures of Lesch-Nyhan
and normal lymphocytes. AG resistance is
surely the way to try out such methods now
because we know quite a lot about it. But
the results will still be subject to the doubt:
Are mutants or phenocopies being counted?
Family studies will not be much help here,
since AG-resistance mutations occur in every-
one. I imagine that if the initial studies with
AG resistance, which Albertini is continuing
at the University of Vermont, give neat
results, it might be interesting to apply the
same principle in comparing lymphocytes
from people who have yielded DAP-resistant
fibroblasts (presumed heterozygotes) with
lymphocytes from people presumed to be
normally homozygous.
In general then, we should plan on using
the genetic and phenotypic analysis that is
possible with cells proliferating in vitro to
devise tests that are faster, less expensive
and more compact than the selection methods
being used currently.
These improved tests could include auto-
mated procedures for scanning large popu-
lations of cells for rare, abnormal histo-
chemical phenotypes. For instance, it might
be worthwhile to try and find an inducible
enzyme that has a cheap fluorogenic sub-
strate. The enzyme chosen should not be
inducible in AG-sensitive cells but should be
in AG-resistant cells when AG is present.
One might detect and count the mutants
after brief selection with AG in the pre-
sence of the inducer by adding the sub-
strate and passing the suspension of counted
cells through a device that senses and counts
the fluorescent cells. Methods of this general
sort would be useful for both direct and
diagnostic testing.
A major difficulty with strictly in vitro
methods is a partial loss of realism: the cells
are removed from the metabolic influences
of the intact human, which sometimes deter-
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There are severe difficulties in solving this
problem with human cells. One approach to
a solution is a host-mediated assay that uses
human cells and nonhuman hosts. Another
approach is to subject human cells in vitro
to conditions that are supposed to simulate
in vivo influences relevant to mutagenesis.
Two questions apply to any mutation de-
tection method: (1) is it genetically sound?
(2) Is it technically practical and sufficiently
economical? I have emphasized the basic
genetic questions that must be answered
if maximum use is to be made of AGr and
DAPr mutants in mutagenesis detection with
human cells. The question about their genetic
soundness is not yet answered but is acces-
sible to experimental analysis. The same
question must be answered for all current
mammalian cell methods that I know of.
Both selection systems have a favorable gene-
tic aspect that I hope can pertain to selec-
tion systems that will be adopted for dis-
covering mutagenic effects: they detect for-
ward mutations in dispensable genes. De-
ficiencies of A-PRT and HG-PRT correspond
to auxotrophic mutations but the methods
for detecting them are more nearly quanti-
tative than other methods for detecting
auxotrophic mutations. The entire variety of
mutational changes that can affect a gene
is sampled. The only equivalent to this whole-
spectrum sensitivity is the study of reverse
mutation using a panel of mutants that re-
sulted from different specified kinds of gene-
tic events spanning the entire spectrum of
mutagenic effects. Original site reversion is
usually a less frequent event than forward
mutation and can be simulated by extragenic
suppressor mutations. Therefore, reversion
studies would substitute a set of tests that
must be individually large enough to detect
a specific kind of mutation for a single,
all-purpose test.
The serious technical limitation called
"metabolic cooperation" (9) afflicts the AG-
resistance selection system and, probably, the
DAP-resistance selection system as used with
human fibroblasts and Chinese hamster cells:
AGr mutants become AG-sensitive pheno-
copies as a result of contact with normal
cells in the presence of AG. Maximum re-
covery of mutants for purposes of quanti-
tation requires that selection be applied to
populations less dense than about 60 cells/
mm2 of surface. This requirement causes
experiments to be larger and more expen-
sive than is desirable. To me, the cost-benefit
ratio will still be small if application of these
methods prevents the dissemination of just
one weak mutagen. Nevertheless, elimina-
tion of the complication created by metabolic
cooperation from these selection systems or
others should be an important objective of
future investigation.
Metabolic cooperation may be insignificant
in cultures of human lymphoblastoid cells
and mouse lymphoma cells. Some cultures of
lymphoblastoid cells have high cloning effi-
ciencies and can be propagated without limit
in vitro. The mouse lymphoma cells have the
added advantage of being unhampered by
major histocompatibility barriers in host-
mediated applications. Both types of cells
may have much to offer in mutagenicity test-
ing. At this time, lymphoblastoid lines ex-
hibit great variability in cloning efficiencies
and in sensitivities to the lethal and mut-
agenic effects of chemical mutagens (10).
Their indefinitely prolonged in vitro propaga-
bility may depend on the presence of a viral
(Epstein-Barr) genome, which might con-
ceivably affect the mutational behavior of
the cells. Nevertheless, human lymphoblas-
toid cells, mouse lymphoma cells, Chinese
hamster cells and, perhaps, others, are po-
tential substitutes for human fibroblasts. It
would be important in some applications to
show that their mutation mechanisms and
mutagenic responsiveness are representative
of normal human cells. They should not be
markedly hyper- or hyporesponsive in com-
parison to normal cells, but the latter is the
more dangerous difference. The only way
this can be determined is by a detailed com-
parison of fibroblast strains and other cell
lines with regard to mutagenic responsive-
ness at several loci. A comparison of DNA
repair mechanisms should be a part of such
studies. Finally, it will be of considerable in-
December 1973 135terest to determine if lymphoblasts and fibro-
blasts from the same person exhibit similar
mutational behavior.
Acknowledgements
This is paper No. 1670 from the Labora-
tory of Genetics, University of Wisconsin,
Madison. Research cited here that was per-
formed in the author's laboratory was sup-
ported by research grants from The National
Institutes of Health (GM-06983, GM-15422
and NIEHS-722095).
REFERENCES
1. Collected Poems of Dylan Thomas. New Direc-
tions, New York, N.Y., 1953.
2. DeMars, R., and Held, K. R. The spontaneous
azaguanine-resistant mutants of diploid human
fibroblasts. Humangenetik 16: 87 (1972).
3. Albertini, R. J., and DeMars, R. Detection and
quantification of x-ray-induced mutation in
cultured, diploid human fibroblasts. Mutation
Res. 18: 199 (1973).
4. Rappaport, H., and DeMars, R. Diaminopurine-
resistant mutants of cultured, diploid human
fibroblasts. Genetics, in press.
5. Van Zeeland, A. A., et al. The role of metabolic
cooperation in selection of hypoxanthine-guanine
phosphoribosyl-transferase (HG-PRT)-deficient
mutants from diploid mammalian cell strains.
Mutation Res. 14: 355 (1972).
6. Shapiro, N. I., et al. Mutagenesis in cultured
mammalian cells. I. Spontaneous gene mutations
in human and Chinese hamster cells. Mutation
Res. 15: 203 (1972).
7. Felix, J. S. Genetic studies on cultured cells
bearing the Lesch-Nyhan mutation (hypoxan-
thine-guanine phosphoribosyltransferase defi-
ciency) with attempts to derepress the X chro-
mosome in heterozygous female cells. Ph.D.
Thesis, University of Wisconsin. 1971.
8. Albertini, R. J. Spontaneous and x-ray induced
mutation in cultured, diploid human cells. Ph.D.
Thesis, University of Wisconsin, 1972. To be
published.
9. Cox, R. P., et al. Communication between normal
and enzyme deficient cells in tissue culture. Exp.
Cell Res. 74: 251 (1972).
10. Sato, K., Slesinski, R. S., and Littlefield, J. W.
Chemical mutagenesis at the phosphoribosyl-
transferase locus in cultured human lympho-
blasts. Proc. Nat. Acad. Sci. U.S. 69: 1244
(1972).
136 Environmental Health Perspectives